
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing potassium iodide, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing potassium iodide are listed in tablet and solution forms. No FDA-approved potassium iodide product is listed in capsule form; capsule products containing it are filed as unapproved drugs.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Potassium iodide is an iodide salt taken by mouth that acts on the thyroid and that a pharmacy may compound when prescribed.
Potassium iodide (KI) supplies iodide to the thyroid gland. In large amounts it fills the thyroid with stable iodine so the gland cannot take up radioactive iodine, and it also temporarily slows the production and release of thyroid hormone. FDA lists iOSAT tablets, ThyroSafe tablets and Mission Pharmacal's Potassium Iodide Oral Solution as FDA-approved nonprescription products, indicated only to block the thyroid in a nuclear radiation emergency. Saturated potassium iodide oral solution (SSKI) is a prescription product marketed without FDA approval; its label lists use as an expectorant in chronic lung disease with thick mucus. StatPearls describes prescribed use in severe hyperthyroidism, before thyroid surgery, and in certain inflammatory skin conditions and sporotrichosis, which are not FDA-approved indications. A prescriber might order it compounded in a strength or form not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Potassium iodide products have no boxed warning. Do not use it if you are allergic to iodine or have dermatitis herpetiformis, hypocomplementemic vasculitis, or nodular thyroid disease with heart disease. Taking it with lithium or antithyroid drugs can increase the risk of low thyroid function and goiter, and taking it with potassium supplements, potassium-sparing diuretics or ACE inhibitors can raise blood potassium to dangerous levels. Longer use can cause low thyroid function or iodism (metallic taste, burning mouth, sore gums, cold-like symptoms). Get medical help right away for trouble breathing or swallowing, swelling of the face or throat, irregular heartbeat or chest pain, and stop and call for a rash, fever or joint pain. The SSKI label warns it can cause fetal goiter and harm. LactMed notes that excess iodine during breastfeeding can cause temporary low thyroid function in infants. Talk to your prescriber or pharmacist about side effects.
Pharmacologic iodide acutely reduces thyroglobulin proteolysis and hormone release and transiently inhibits organification (the Wolff-Chaikoff effect), with escape in normal glands within 2 to 4 weeks through reduced sodium-iodide symporter expression. Graves disease increases sensitivity to this effect; Hashimoto thyroiditis and other defects in autoregulation predispose to iodide-induced hypothyroidism, and long-standing iodine-deficient goiter to Jod-Basedow thyrotoxicosis. In a radiation emergency, KI saturates the thyroid so radioiodine is excreted in urine; StatPearls notes protection declines with time after exposure, and FDA states KI is not a general radioprotective agent. Labeled indications: thyroid blocking in a nuclear radiation emergency (iOSAT, NDA; ThyroSafe and Mission oral solution, ANDA). SSKI, an unapproved product, carries an expectorant indication. StatPearls describes use for thyroid storm, preoperative preparation for thyroidectomy, sporotrichosis and neutrophilic dermatoses; these are not FDA-approved indications. Use caution in Addison's disease, cardiac disease, hyperthyroidism, myotonia congenita, tuberculosis and renal impairment. Iodide can alter thyroid function tests. Dosing is per prescriber. Monitor potassium and renal function, consider TSH with use beyond one month, and follow FDA guidance on thyroid monitoring in neonates, infants, and pregnant or nursing women given repeat doses.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth